Free shipping on all orders over $ 500

 About 30 results found for searched term "Checkpoint" (0.095 seconds)

Cat.No.  Name Target
M1665 AZD7762 Checkpoint
AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.
M1764 PF-477736 Checkpoint
PF-0044736
PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively.
M3686 AZD7762 hydrochloride Checkpoint
AZD-7762 HCl
AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.
M5156 CCT241533 hydrochloride Checkpoint
CCT241533 HCl
CCT241533 hydrochloride is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM.
M5648 Floxuridine DNA/RNA Synthesis
Deoxyfluorouridine; FDUR; NSC 27640
Floxuridine (5-fluorouracil 2'-deoxyriboside) is a pyrimidine analogue that is also an antitumor metabolite of oncology. Floxuridine inhibits the Poly(ADP-Ribose) polymerase and induces DNA damage in vitro by activating ATM and ATR checkpoint signaling pathways. Floxuridine is an effective inhibitor of Staphylococcus aureus infection and can induce apoptosis. Floxuridine is resistant to HSV and CMV viruses.
M6100 Nivolumab PD-1/PD-L1
BMS-936558, ONO-4538, MDX-1106;Opdivo
Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice).
M6102 Pembrolizumab PD-1/PD-L1
Lambrolizumab; MK-3475;Keytruda
Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required).
M6104 Ipilimumab Checkpoint
MDX-010, BMS-734016;Yervoy
Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
M7255 SB 218078 Others
SB 218078 is a inhibitor of checkpoint kinase 1 (Chk1).
M7986 OM137 Others
OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint.
M9897 GB1107 Galectin
GB-1107
GB1107 is a potent, selective, orally active galectin-3 inhibitor with Kd of 37 nM. GB1107 inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. GB1107 potentiates the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules.
M10129 CCT245737 Checkpoint
SRA737; PNT-737
CCT245737 is a potent, selective and orally active checkpoint kinase 1 (CHK1) inhibitor, with IC50 values of 1.3 nM, 2440 nM and 30 nM for CHK1, CHK2 and G2 check point abrogation, respectively.
M10130 AZD0156 ATM/ATR
AZD-0156
AZD0156 is a potent, selective and orally active ATM inhibitor with an IC50 of 0.58 nM. AZD0156 inhibits ATM mediated signal transduction, prevents DNA damage checkpoint activation, damages DNA damage repair, and induces tumor cell apoptosis.
M10288 BMS-1001 PD-1/PD-L1
BMS-1001 free base; BMS1001
Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r.
M10476 GDC-0575 (ARRY-575) Checkpoint
RG7741; ARRY575; AK-687476
GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM.
M10583 RRX-001 NLR
ABDNAZ
Rrx-001 is a hypoxic selective epigenetic factor that has been used as a radiation or chemotherapy sensitizer to induce apoptosis. Rrx-001 is an immune checkpoint inhibitor that down-regulates CD47 and SIRP-α. Rrx-001 is also an effective inhibitor of G6PD with strong antimalarial activity. Rrx-001 inhibits the expression of CD47 in tumor cells by inhibiting c-myC, a positive regulator of CD47.
M11251 Gartisertib ATM/ATR
VX-803; M4344; ATR inhibitor 2
Gartisertib (VX-803) is an ATP-competitive, orally active, selective ATR inhibitor with Ki<150 pM. Gartisertib inhibits atR-driven phosphorylation of checkpoint kinase-1 (Chk1) with an IC50 value of 8 nM. It has antitumor activity.
M13620 CCT244747 Checkpoint
CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM.
M13622 Prexasertib Checkpoint
LY2606368
Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM.
M13623 Prexasertib dimesylate Checkpoint
LY2606368 dimesylate
Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM.
M20859 AUNP-12 PD-1/PD-L1
Aur-012, Aurigene-012, Aurigene NP-12
AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
M21002 BOS172722 Others
BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM.
M21501 Monalizumab Checkpoint
IPH2201
Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC).
M24851 Tiragolumab TIGIT
Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors.
M24930 Fianlimab Others
REGN3767
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.
M24934 Ontorpacept Others
TTI-621
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
M24952 Zalifrelimab Others
AGEN1884
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.
M24960 Neihulizumab Apoptosis
ALTB-168; Anti-PSGL1/CD162 Reference Antibody
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.
M25004 Tinurilimab Others
BAY 1834942
Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.
M25080 Vudalimab PD-1/PD-L1
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.